ArticleMaterials (Basel, Switzerland)2025
Development of a High-Performance Composite Mortar for Ultra-High-Strength Preplaced Aggregate Concrete-Filled Steel Tubes (PACFSTs).
Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study developed a high-performance composite mortar with a low water-to-binder (W/B) ratio to improve the mechanical strength and volumetric stability of preplaced aggregate concrete-filled steel tubes (PACFST). Silica fume was incorporated to optimize the interfacial transition zone (ITZ) between the matrix and coarse aggregates. The effects of the sand-to-binder (S/B) ratio, water-to-binder (W/B) ratio, and expansive agent content on the flowability, compressive strength, and volume stability of the composite mortar were systematically analyzed. Experimental tests were conducted using vibration-free molded specimens, and the influence of different S/B ratios (0.8-1.4), W/B ratios (0.26-0.32), and expansive agent dosages (0-8%) on mortar properties was evaluated. The results indicate that an optimal S/B ratio of 1.2 significantly enhances flowability and strength, whereas further increases offer limited improvement. Reducing the W/B ratio enhances strength, with a decrease from 0.32 to 0.28 leading to a 23.4% increase in 28-day compressive strength. Additionally, a 6% expansive agent dosage reduces 90-day shrinkage by 13.1% while maintaining high compressive strength. The optimized PAC achieved a 28-day compressive strength of 115.9 MPa, with an 11.6% increase in 7-day strength and a 51.2% reduction in 90-day shrinkage compared to conventional C100 concrete. These findings provide theoretical guidance for designing high-strength, low-shrinkage PAC, offering insights for bridge, tunnel, and high-rise building applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.